SAN JOSE — A diagnostic platform designed to surface rare diseases months earlier than traditional pathways is moving from lab demos to hospital pilots. The system cross‑references routine blood work, imaging markers, and symptom timelines, then suggests a shortlist of possibilities for clinicians to verify.

Doctors involved in the trial describe it as a triage tool rather than an oracle. In practice, it nudges teams to order confirmatory tests sooner and to route complex cases toward genetic counselors and specialty clinics.

Health authorities say the key question is not whether the model can spot patterns, but whether hospitals can audit decisions when something goes wrong. The pilot sites are required to keep an explanation log for each recommendation and to track false positives by age, sex, and ethnicity.